Work

Case Report: Infliximab for hydroxychloroquine-induced AGEP with IL17A and IL36RN mutations: a case report and management considerations

Year: 2025

Type: article

Abstract: Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous drug reaction that typically resolves rapidly following withdrawal of the offending drug and administration of systemic corticosteroids. Infliximab, a biologic agent that inhibits TNF-α, is widely used in the treatment of various inflammatory diseases. Individuals with specific genetic risk factors may be more susceptible to severe drug-induced cutaneous reactions. Here, we report the first case of successful infliximab treatment in a pregnant woman with IL17A and IL36RN mutations who developed severe AGEP after 24 days of hydroxychloroquine use and failed to respond to conventional therapy.

Source: Frontiers in Pharmacology

DOI: 10.3389/fphar.2025.1580170

Authors: Xiaoyun Jiang, Chunting Hua, Chenxi Feng, Hao Cheng

Institutions: Sir Run Run Shaw Hospital, Zhejiang University

Language: English

Topic: Drug-Induced Adverse Reactions

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801